C
Chao-Yin Chen
Researcher at Amgen
Publications - 4
Citations - 1834
Chao-Yin Chen is an academic researcher from Amgen. The author has contributed to research in topics: Anemia & Kidney disease. The author has an hindex of 3, co-authored 4 publications receiving 1701 citations.
Papers
More filters
Journal ArticleDOI
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Jan Feyzi,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto +19 more
TL;DR: The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event ordeath or a renal event) and was associated with an increased risk of stroke.
Journal ArticleDOI
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto,Hajime Uno +18 more
TL;DR: With several-fold more patient years and a placebo arm, TREAT will provide a robust estimate of the safety and efficacy of darbepoetin alfa and generate prospective data regarding the risks of major cardiovascular and renal events in a contemporarily managed cohort of patients with type 2 diabetes, CKD, and anemia.
Journal ArticleDOI
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: An analysis of the TREAT (trial to reduce cardiovascular events with aranesp therapy) placebo arm
Hicham Skali,Julie Lin,Marc A. Pfeffer,Chao-Yin Chen,Mark E. Cooper,John J.V. McMurray,Allen R. Nissenson,Allen R. Nissenson,Giuseppe Remuzzi,Jerome Rossert,Patrick S. Parfrey,Nairne Scott-Douglas,Ajay K. Singh,Robert D. Toto,Hajime Uno,Peter Ivanovich +15 more
TL;DR: Most patients with moderate anemia, non-dialysis-dependent CKD, and type 2 diabetes are able to maintain a stable Hb level without implementing long-term erythropoiesis-stimulating agent therapy.
Original Investigation Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm
Hicham Skali,Julie Lin,Marc A. Pfeffer,Chao-Yin Chen,Mark E. Cooper,John Mcmurray,Allen R. Nissenson,Giuseppe Remuzzi,Patrick S. Parfrey,Nairne Scott-Douglas,Ajay K. Singh +10 more
TL;DR: In this paper, the authors describe the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus.